




Searching News Database: Cetuximab
HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
HSMN NewsFeed - 1 Feb 2011
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
HSMN NewsFeed - 1 Jun 2009
Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients
Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
HSMN NewsFeed - 31 Jul 2008
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
HSMN NewsFeed - 1 Feb 2007
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Additional items found! 57

Members Archive contains
57 additional stories matching:
Cetuximab
(Password required)
Cetuximab
(Password required)